Arch Biopartners Arranges Non-Brokered Private Placement

Executive Summary

• Arch Biopartners Inc. announced a non‑brokered private placement of 480,769 common shares at $1.04 CAD per share for gross proceeds of $500,000 CAD.
• All shares are being purchased by an officer of the company (related‑party transaction) and will be subject to a four‑month‑plus hold period.
• Proceeds will be used for general working capital and operating expenses not covered by existing human‑trial funding grants.

Key Details

• Offering Size: 480,769 common shares at $1.04 CAD per share.
• Gross Proceeds: $500,000 CAD.
• Closing Date: Expected to close on November 12, 2025, subject to regulatory approvals and customary closing conditions.
• Investor: All shares are being issued to an officer of Arch Biopartners (related‑party transaction).
• Regulatory Exemption: Transaction exempt from formal valuation and minority shareholder approval under MI 61‑101 because consideration does not exceed 25 % of market capitalization.
• Hold Period: Shares subject to a lock‑up of four months and one day from the closing date.
• Finders’ Fees: No finders’ fees will be paid in connection with the offering.
• Use of Proceeds: General working capital and certain operating expenses not covered by human‑trial funding grants.
• Outstanding Shares Post‑Offering: Company has 66,356,366 common shares outstanding (pre‑offering).

Notable Quotes

(No executive quotes were included in the release.)